ArticleJournal of gastrointestinal oncology2024
Development and validation of a prognostic nomogram for elderly-onset pancreatic neuroendocrine carcinoma: a prospective cohort study from the SEER database.
Article in Journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of elderly-onset pancreatic neuroendocrine carcinoma (PanNEC) is increasing. This study investigated independent risk factors affecting cancer-specific survival (CSS) and constructed a nomogram to predict CSS in patients with elderly-onset PanNEC. Methods: PanNEC patients older than 50 years from the Surveillance, Epidemiology, and End Results database were retrospectively selected from 2010 to 2021 and were randomly divided into a training set and a validation set. Independent factors affecting CSS were selected by univariate and multivariate analyses. The nomogram was built using significant variables. The discrimination and calibration of the nomogram were evaluated by the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis. Results: A total of 407 patients were selected and randomly assigned to a training set or a validation set at a 6:4 ratio. In the selected population, 227 individuals (55.8%) were male, 313 (76.9%) were white, with a mean age of 69.4 years. Among them, 318 individuals (78.1%) died due to the tumor, with a CSS time of 6 months. Multivariate Cox analysis showed that age [hazard ratio (HR): 1.56, 95% confidence interval (CI): 1.10-2.22, P=0.01], surgery (HR: 2.32, 95% CI: 1.27-4.23, P=0.006), chemotherapy (HR: 2.39, 95% CI: 1.68-3.38, P<0.001), tumor, nodes, and metastasis (TNM) stage (HR: 3.96, 95% CI: 1.19-13.19, P=0.03), and liver metastasis (HR: 1.75, 95% CI: 1.16-2.65, P=0.008) were independent risk factors that shortened CSS. The AUCs of the nomogram for the 6-month, 1-year, and 2-year CSS were 0.826, 0.791, and 0.8 in the training set and 0.848, 0.775, and 0.781 in the validation set, respectively. Calibration curves showed that the nomogram could accurately predict the 6-month, 1-year, and 2-year CSS in both datasets. Furthermore, decision curve analysis indicated that the nomogram had clinical benefits. Conclusions: The nomogram for CSS in patients with elderly-onset PanNEC showed good predictive power, enabling clinicians to understand patient's prognosis and make appropriate decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.